Propisergide

In today's world, Propisergide plays a vital role in various areas of life. Its importance is reflected in society, the economy, politics, culture and people's daily lives. Propisergide has been the object of study and interest in different times and contexts, which demonstrates its relevance over time. In this article, we will explore the impact and influence of Propisergide on different aspects of society, as well as its evolution throughout history. Additionally, we will analyze how Propisergide continues to be a topic of debate and reflection today, and how its meaning has changed over time.

Propisergide
Clinical data
Other namesErgalgin; N-Methylergobasine; N-Methylergonovine; N-Methylergometrine; 1-Methylergonovine
Drug classSerotonin receptor modulator; Antimigraine agent
Identifiers
  • (6aR,9R)-N--4,7-dimethyl-6,6a,8,9-tetrahydroindoloquinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H25N3O2
Molar mass339.439 g·mol−1
3D model (JSmol)
  • C(CO)NC(=O)1CN(2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C
  • InChI=1S/C20H25N3O2/c1-12(11-24)21-20(25)14-7-16-15-5-4-6-17-19(15)13(9-22(17)2)8-18(16)23(3)10-14/h4-7,9,12,14,18,24H,8,10-11H2,1-3H3,(H,21,25)/t12-,14+,18+/m0/s1
  • Key:XUKAVPATXGYVKJ-WPKBUWHJSA-N

Propisergide (INNTooltip International Nonproprietary Name), also known as ergalgin or as N-methylergometrine or 1-methylergometrine, is a serotonin receptor modulator and antimigraine agent of the ergoline and lysergamide families which was never marketed.[1][2][3][4] It is the 1-methyl derivative of ergometrine (ergonovine) and is a close analogue of methylergonovine and methysergide.[5] The drug was first described in the literature by 1962[6] and then further around 1980 and after.[4][7][8]

References

  1. ^ Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. ISBN 978-1-4757-2085-3. Retrieved 13 March 2025.
  2. ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Taylor & Francis. ISBN 978-0-412-46630-4. Retrieved 13 March 2025.
  3. ^ Waldman M, Fraczkiewicz R, Clark RD (September 2015). "Tales from the war on error: the art and science of curating QSAR data". Journal of Computer-Aided Molecular Design. 29 (9): 897–910. Bibcode:2015JCAMD..29..897W. doi:10.1007/s10822-015-9865-0. PMID 26290258.
  4. ^ a b Oelszner W (1980). "Displacement of specific serotonin and lysergic acid diethylamide binding by Ergalgin, a new antiserotonin drug". Acta Biologica et Medica Germanica. 39 (8–9): 897–901. PMID 7282219.
  5. ^ "Propisergide". PubChem. U.S. National Library of Medicine. Retrieved 13 March 2025.
  6. ^ World Health Organization (1962). Cumulative List of Proposed International Non-proprietary Names for Pharmaceutical Preparations. 1962-. World Health Organization. ISBN 978-92-4-056013-0. Retrieved 13 March 2025. {{cite book}}: ISBN / Date incompatibility (help)
  7. ^ Bartsch R, Nowak R (January 1979). "Pharmacological Evaluation of a New Ergolin Derivative (Ergalgin)". Die Pharmazie. 34 (5–6). Eschborn, Germany: Govi-Verlag Pharmazeutischer GmbH: 358.
  8. ^ Harhammer R, Morgenstern R, Ott T (1992). "Pharmacological Effects of Ergalgin, a Potent Antagonist at Central and Peripheral 5-Ht (2) Receptors". Biogenic Amines. 8 (3–4): 267–275.
Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.